Plasma Sialic Acid as a Marker of the Effect of the Treatment on Metastatic Colorectal Cancer

Author： Painbeni T.   Gamelin E.   Cailleux A.   Le Bouil A.   Boisdron-Celle M.   Daver A.   Larra F.   Allain P.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.33, Iss.13, 1997-11, pp. : 2216-2220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in the treatment of metastatic colorectal cancer

By Caprioni Francesco   Fornarini Giuseppe  

Future Oncology, Vol. 3, Iss. 2, 2007-04 ,pp. : 141-148

Future Medicine

Access to resources Recommend Favorite

Intermittent therapy in the palliative treatment of metastatic colorectal cancer

By Powell James   Adams Richard  

Colorectal Cancer, Vol. 2, Iss. 3, 2013-06 ,pp. : 219-232

Future Medicine

Access to resources Recommend Favorite

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU - a retrospective comparison of treatment regimens

By Iveson T.J.   Hickish T.   Schmitt C.   Van Cutsem E.  

European Journal of Cancer, Vol. 35, Iss. 13, 1999-12 ,pp. : 1796-1804

Elsevier

Access to resources Recommend Favorite

XELIRI compared with FOLFIRI as a secondline treatment in patients with metastatic colorectal cancer

By                  

Oncology Letters, Vol. 8, Iss. 4, 2014-01 ,pp. : 1864-1872

Spandidos Publications

Access to resources Recommend Favorite

Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer

By Cremolini Chiara   Schirripa Marta   Loupakis Fotios   Falcone Alfredo  

Colorectal Cancer, Vol. 2, Iss. 5, 2013-10 ,pp. : 411-417

Future Medicine

Access to resources Recommend Favorite